RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Perspective Therapeutics - Stock

Perspective Therapeutics EBIT 2024

Perspective Therapeutics EBIT

-52.57 M USD

Ticker

CATX

ISIN

US46489V1044

WKN

A0MQNM

In 2024, Perspective Therapeutics's EBIT was -52.57 M USD, a 28.41% increase from the -40.94 M USD EBIT recorded in the previous year.

The Perspective Therapeutics EBIT history

YEAREBIT (undefined USD)
2027e-
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-
2014-
2013-
2012-
2011-
2010-
2009-
2008-
2007-
2006-
2005-
2004-

Perspective Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Perspective Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Perspective Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Perspective Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Perspective Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Perspective Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Perspective Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Perspective Therapeutics’s growth potential.

Perspective Therapeutics Revenue, Profit, and EBIT History

DatePerspective Therapeutics RevenuePerspective Therapeutics EBITPerspective Therapeutics Net Income
2027e14.4 M undefined-52.05 M undefined0 undefined
2026e571,536.6 undefined-61.4 M undefined-71.63 M undefined
2025e327,828 undefined-57.64 M undefined-70.54 M undefined
2024e534,480 undefined-52.57 M undefined-64.03 M undefined
20231.43 M undefined-40.94 M undefined-46.51 M undefined
20223.55 M undefined-7.59 M undefined-7.34 M undefined
202110.8 M undefined-7.39 M undefined-7.27 M undefined
202010.05 M undefined-3.44 M undefined-3.39 M undefined
20199.68 M undefined-3.48 M undefined-3.46 M undefined
20187.31 M undefined-5.27 M undefined-5.16 M undefined
20175.92 M undefined-6.73 M undefined-6.71 M undefined
20164.76 M undefined-6.31 M undefined-6.17 M undefined
20154.77 M undefined-5.08 M undefined-4.72 M undefined
20144.61 M undefined-4.34 M undefined-3.69 M undefined
20134.22 M undefined-4.59 M undefined-6.7 M undefined
20124.53 M undefined-4.07 M undefined-3.87 M undefined
20115.07 M undefined-3.6 M undefined-3.5 M undefined
20105.24 M undefined-2.96 M undefined-2.85 M undefined
20095.29 M undefined-4.01 M undefined-4.04 M undefined
20085.42 M undefined-6.47 M undefined-6.17 M undefined
20077.16 M undefined-8.8 M undefined-8.56 M undefined
20065.74 M undefined-9.7 M undefined-9.61 M undefined
20051.99 M undefined-7.2 M undefined-8.22 M undefined
2004200,000 undefined-3.98 M undefined-4.27 M undefined

Perspective Therapeutics stock margins

The Perspective Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Perspective Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Perspective Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Perspective Therapeutics's sales revenue. A higher gross margin percentage indicates that the Perspective Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Perspective Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Perspective Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Perspective Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Perspective Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Perspective Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Perspective Therapeutics Margin History

Perspective Therapeutics Gross marginPerspective Therapeutics Profit marginPerspective Therapeutics EBIT marginPerspective Therapeutics Profit margin
2027e23.1 %-361.36 %0 %
2026e23.1 %-10,742.78 %-12,533.2 %
2025e23.1 %-17,582.55 %-21,518.7 %
2024e23.1 %-9,836.01 %-11,980.31 %
202323.1 %-2,855.02 %-3,243.24 %
202223.1 %-213.8 %-206.76 %
202142.78 %-68.43 %-67.31 %
202050.95 %-34.23 %-33.73 %
201952.89 %-35.95 %-35.74 %
201841.72 %-72.09 %-70.59 %
201731.08 %-113.68 %-113.34 %
201617.65 %-132.56 %-129.62 %
20152.73 %-106.5 %-98.95 %
20143.69 %-94.14 %-80.04 %
2013-4.74 %-108.77 %-158.77 %
20123.31 %-89.85 %-85.43 %
201113.81 %-71.01 %-69.03 %
201022.14 %-56.49 %-54.39 %
200913.8 %-75.8 %-76.37 %
2008-6.46 %-119.37 %-113.84 %
2007-2.09 %-122.91 %-119.55 %
2006-1.05 %-168.99 %-167.42 %
2005-91.46 %-361.81 %-413.07 %
2004-635 %-1,990 %-2,135 %

Perspective Therapeutics Aktienanalyse

What does Perspective Therapeutics do?

The company IsoRay Inc is a leading global company in the field of brachytherapy and specializes in the development of novel medical devices for the treatment of cancer. The company's history dates back to the 1980s when it was founded by a team of doctors and scientists. IsoRay Inc's business model is based on the research, development, and manufacturing of medical products used in the treatment of cancer. Brachytherapy is a particularly important focus. This involves a treatment method where radioactive seeds or sources are directly implanted into the tumor. The radiation destroys the cancer cells without damaging the surrounding tissue. IsoRay Inc's product range includes a variety of medical devices and accessories for conducting brachytherapy procedures. The company specializes in the development of high-tech products that enable precise and effective radiation therapy. This includes, for example, radioactive seeds that are directly implanted into the tumor or apparatuses that can selectively use radiation in specific structures of the body. A special focus of IsoRay Inc is computer-assisted planning of brachytherapy treatments. The tumor is precisely measured and the radiation sources are individually customized based on the data to achieve an optimal radiation dose. This planning is done using modern software and is an important factor for the successful treatment of cancer. In addition to research and development of medical products, IsoRay Inc also encompasses the production and distribution of these products. The company operates in more than 30 countries worldwide and collaborates closely with numerous clinics and practices to research and improve new technologies in the field of radiation therapy. One of IsoRay Inc's most well-known products is the "Cesium-131 Brachytherapy seed." This radioactive seed is particularly small and therefore ideal for targeted radiation therapy of tumors. It is used in almost all clinical areas worldwide and is considered particularly safe and effective. Other products of the company include the "Gladius™ Applicator Needle," a device for precise placement of radiation sources in tumors, as well as "Intraoperative Application Systems" that enable effective radiation therapy during surgery. Overall, IsoRay Inc is considered an innovative and successful company in the field of brachytherapy and radiation therapy. The constant development and improvement of its own products is a key factor for the company's success. High quality and close collaboration with research and practice are central to its operations. Perspective Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Perspective Therapeutics's EBIT

Perspective Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Perspective Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Perspective Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Perspective Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Perspective Therapeutics Stock

How much did Perspective Therapeutics achieve in EBIT for the current year?

In the current year, Perspective Therapeutics has achieved an EBIT of -52.57 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Perspective Therapeutics.

How has the EBIT of Perspective Therapeutics developed in recent years?

The EBIT of Perspective Therapeutics has increased by 28.408% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Perspective Therapeutics?

The EBIT of Perspective Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Perspective Therapeutics pay?

Over the past 12 months, Perspective Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Perspective Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Perspective Therapeutics?

The current dividend yield of Perspective Therapeutics is .

When does Perspective Therapeutics pay dividends?

Perspective Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Perspective Therapeutics?

Perspective Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Perspective Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Perspective Therapeutics located?

Perspective Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Perspective Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Perspective Therapeutics from 6/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/19/2024.

When did Perspective Therapeutics pay the last dividend?

The last dividend was paid out on 6/19/2024.

What was the dividend of Perspective Therapeutics in the year 2023?

In the year 2023, Perspective Therapeutics distributed 0 USD as dividends.

In which currency does Perspective Therapeutics pay out the dividend?

The dividends of Perspective Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Perspective Therapeutics

Our stock analysis for Perspective Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Perspective Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.